Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review.
J Child Adolesc Psychopharmacol
; 30(4): 267-272, 2020 05.
Article
en En
| MEDLINE
| ID: mdl-31825249
ABSTRACT
Objective:
To examine the potential effectiveness and tolerability of cariprazine in pediatric bipolar and psychotic disorders.Methods:
We retrospectively reviewed the electronic health records of patients <21 years of age prescribed cariprazine to treat bipolar and psychotic disorders. Adverse effects, tolerability, therapeutic response (Clinical Global Impression-Improvement [CGI-I]), and severity of illness (Clinical Global Impression-Severity [CGI-S]) were determined through manual chart review.Results:
We identified 16 patients aged 6-20 years who were treated with cariprazine (initial dose 1.5 mg/day, interquartile range [IQR], 1.5-1.5; endpoint dose 3 mg/day, IQR, 1.5-4.5). No serious adverse events were reported, but the most commonly reported side effect was weight gain (n = 3, 19%). Of the 14 patients for whom baseline and endpoint body mass index (BMI) data were available, neither changes in BMI (p = 0.391; 0.54 kg/m2, IQR, -0.33 to 1.38) nor BMI percentile (p = 0.71; 0.36%, IQR, -0.49 to 3.97) significantly differed between baseline and endpoint. However, patients receiving ≥4.5 mg/day had a significantly greater BMI increases during the course of treatment compared with those receiving ≤3 mg/day (p = 0.034; -1.14 kg/m2, IQR, -3.65 to 0.53 vs. 1.01 kg/m2, IQR, 0.17-4.88). CGI-S scores (p = 0.016; 4.5, IQR, 4-5 vs. 4, IQR, 3-4) significantly differed from baseline to endpoint. The response rate was 44% (n = 7/16), with responders being prescribed higher doses (p = 0.005; 6 mg/day, IQR, 4.875-6 vs. 3 mg/day, IQR, 3-4.125).Conclusions:
Cariprazine may be well tolerated and effective for pediatric bipolar and psychotic disorders; however, compared with higher doses, total daily doses ≤3 mg/day appear to be more tolerable. Prospective controlled studies to further evaluate cariprazine in youth are needed.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
Problema de salud:
1_sistemas_informacao_saude
Asunto principal:
Piperazinas
/
Trastornos Psicóticos
/
Antipsicóticos
/
Trastorno Bipolar
Tipo de estudio:
Guideline
/
Observational_studies
/
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Child Adolesc Psychopharmacol
Asunto de la revista:
PEDIATRIA
/
PSICOFARMACOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos